Harvard Medical School, Massachusetts General Hospital, 55 Fruit Street, Boston, 02114, MA, USA.
Head Neck Pathol. 2022 Mar;16(1):101-109. doi: 10.1007/s12105-022-01411-2. Epub 2022 Mar 21.
In the 5th edition of the World Health Organization (WHO) Classification of Head and Neck Tumours, the discussion of hematolymphoid proliferations is substantially reorganized and expanded in comparison to the prior edition. The 5th edition includes, in addition to hematolymphoid neoplasms, reactive lymphoid proliferations. Much more information on hematolymphoid proliferations that commonly affect cervical lymph nodes, in addition to those affecting extranodal sites in the head and neck, is included. For the first time, there are dedicated sections on multiple entities, including recently described lymphoproliferative disorders such as EBV+ mucocutaneous ulcer and pediatric-type follicular lymphoma, and several types of histiocytic neoplasms. Tremendous advances have been made in understanding the genetic features that underlie the pathogenesis of hematolymphoid neoplasms, and these have been incorporated into the WHO Classification.
在世界卫生组织（WHO）第五版头颈部肿瘤分类中，与前一版相比，血液淋巴组织增生的讨论在结构上进行了实质性的重组和扩充。第五版除了血液淋巴肿瘤外，还包括反应性淋巴组织增生。与影响头颈部结外部位的血液淋巴组织增生相比，该版纳入了更多常见于颈部淋巴结的血液淋巴组织增生的信息。首次出现了多个实体的专门章节，包括最近描述的淋巴增生性疾病，如 EBV+黏膜溃疡性疾病和儿童型滤泡性淋巴瘤，以及几种组织细胞肿瘤。在理解血液淋巴肿瘤发病机制的遗传特征方面取得了巨大进展，这些进展已被纳入 WHO 分类。
